Last Updated: 09 Nov 2024
Executive Summary
EXACT Sciences Corporation (EXAS) is a leading provider of cancer screening and diagnostic tests. The company's products are used to detect and diagnose a variety of cancers, including colorectal, breast, and lung cancer. EXAS has a strong track record of growth and profitability, and its products are used by millions of patients worldwide.
Company Overview
EXAS was founded in 1995 and is headquartered in Madison, Wisconsin. The company's products are sold through a network of distributors and sales representatives. EXAS has a strong research and development pipeline, and it is constantly developing new products and technologies.
Fundamental Analysis
EXAS is a financially sound company with a strong balance sheet and a history of profitability. The company's revenue has grown steadily in recent years, and its earnings per share have also increased. EXAS has a strong cash flow from operations, and it is able to generate significant amounts of free cash flow.
Technical Analysis
EXAS's stock price has been in a downtrend in recent months. The stock is currently trading below its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is also below 50, which indicates that the stock is oversold.
Short Term Outlook
The short-term outlook for EXAS is mixed. The stock's technical indicators are bearish, but the company's fundamentals are strong. The stock could continue to decline in the short term, but it is also possible that the stock could rebound.
Long Term Outlook
The long-term outlook for EXAS is positive. The company has a strong market position, a strong research and development pipeline, and a history of profitability. The company's products are used by millions of patients worldwide, and the demand for cancer screening and diagnostic tests is expected to continue to grow in the years to come.
Analyst Recommendations
The majority of analysts who cover EXAS have a Buy or Strong Buy rating on the stock. The average analyst target price for EXAS is $72.60, which represents a potential upside of over 40% from the current price.
